Kyiv Science News (Ukraine)

Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD.

There are many different drug targets expressed in brain tissue. The delivery of drugs to central nervous system (CNS) is complicated by blood brain barrier (BBB) which controls entry of drugs into CNS.

The preclinical drug-discovery process requires the screening of millions of small organic molecules to find a suitable lead compound for one ultimately successful outcome.

Biologically active molecule is a broad term comprising a variety of compounds possessing biological activity.Our company, OTAVA Ltd., provides a wide range of biologically active compounds modulating activity of distinct targets.

In recent years, remarkable progress has been made and miraculous results produced in the field of synthetic chemistry. However, searching for desired chemical compounds among variety of chemical databases becomes more and more complex.

OTAVA Ltd. offers a new set of target-focused libraries with Enhanced Intellectual Property Potential (EIPL®).

New technology for virtual screening improving